![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Tag: Coronavirus information (COVID-19)
Press Releases
CureVac and Rentschler Biopharma ramp up Manufacturing of COVID-19 Vaccine, CVnCoV
CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Rentschler Biopharma SE, a leading...
News
Lilly Partners with Area Health Systems to Help Enable Access to Important Antibody Infusion Therapies for COVID-19 Patients
Eli Lilly and Company has partnered with local health systems to launch dedicated infusion center locations serving central, northern, and now southern Indiana that...
News
Valneva Announces UK Government Exercise of Option for 40 Million Doses of its Inactivated, Adjuvanted COVID-19 Vaccine
Valneva SE , a specialty vaccine company focused on prevention against diseases with major unmet needs, reported that the UK Government has exercised its...
Clinical Trials
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint,...
News
REGEN-COV Antibody Cocktail Is Active Against SARS-CoV-2 Variants First Identified in the UK and South Africa
Regeneron Pharmaceuticals, Inc. announced that researchers in Dr. David Ho's Columbia University lab and Regeneron scientists have independently confirmed that REGEN-COVTM (casirivimab and imdevimab...
News
COVID-19 Vaccine AstraZeneca authorised for use in the EU
AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorisation (CMA) in the EU for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in...
Press Releases
Novartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccine
Novartis announced that it has signed an initial agreement to leverage its manufacturing capacity and capabilities in order to address the COVID-19 pandemic by...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read